SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Market Gems:Stocks w/Strong Earnings and High Tech. Rank
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Jenna who wrote (90193)3/26/2000 1:33:00 PM
From: Jenna  Read Replies (2) of 120523
 
ARTC Promising earnings play and intermediate hold. I've traded it and held it as position trades in the past for up to a few weeks. Earnings out 4/03 unconfirmed and looking for 766% earnings per share increase.

Sales are estimated to grow 70 to 80 percent as well
next several years earnings per share

ARTC earnings estimate for next year is $1.79/per share. and it sports a low P/E for that rate of earnings and growth

FDA Clears ArthroCare's Skin Resurfacing System
Key Patent for Treatment of Wrinkle Reduction Issues
SUNNYVALE, Calif.--(BW HealthWire)--March 22, 2000--ArthroCare Corporation (Nasdaq:ARTC - news) today announced it has received 510 (k) clearance from the United States Food and Drug Administration (FDA) to market the company's Coblation©-based cosmetic surgery system for skin resurfacing for the treatment of wrinkles. In related news, the company also announced that the United States Patent Office has issued a new patent with claims that are broadly directed to the use of radio frequency energy for skin resurfacing for the treatment of wrinkles. This recently issued patent complements ArthroCare's existing patent portfolio, which covers, among other things, Coblation technology and its use for cosmetic surgery.

In the multi-site clinical trial data submitted to the FDA, over 100 patients received skin resurfacing treatments with the ArthroCare system, and were followed for six months. Clinical results demonstrated that nearly 90 percent of all patients treated were highly satisfied with the results of their treatment. Clinical results have been submitted and accepted for publication shortly in a leading professional journal.

``We are very excited with the results of the clinical trials,' said Roy C. Grekin, M.D, Clinical Professor of Dermatology, University of California-San Francisco and chief investigator of the skin resurfacing clinical trials. ``My patients treated with Coblation technology experienced a consistent and predictable reduction in wrinkles, with less pain and more rapid recovery, than we've typically seen with lasers.'

The Coblation-based cosmetic surgery system will be marketed through ArthroCare's strategic partnership with Inamed Corporation. Inamed is a worldwide leader in the cosmetic and plastic surgery product markets and will market the system through its McGhan division under the Refinity(TM) and Coblation brand names. The FDA previously granted ArthroCare clearance to market the company's cosmetic surgery system for general dermatological use in August 1998. The system is CE marked in Europe and approved for sale in other international markets.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News